LEM4 overexpression in ER+ breast cancer cells confer estrogen independence and tamoxifen resistance through activation of both the cyclin D-CDK4/6- Retinoblastoma-1 (Rb) pathway and ERα signaling [75]. Here, ESR1 is linked to breast cancer.